|Table of Contents|

Expression of miR-101 and its relationship with clinical pathological parameters in endometrial carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 03
Page:
436-440
Research Field:
Publishing date:

Info

Title:
Expression of miR-101 and its relationship with clinical pathological parameters in endometrial carcinoma
Author(s):
Zhou Feimei; Ma Xiaoxin
Department of Obstetrics and Gynecology，Shengjing Hospital of China Medical University，Liaoning Shenyang 110004，China.
Keywords:
microRNA; miR-101; endometrial carcinoma; clinical pathological parameters; progress; clinical significance
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2017.03.025
Abstract:
Objective：To investigate expression of miR-101 and its relationship with clinical pathological parameters in endometrial carcinoma，in order to explore the pathogenesis of endometrial carcinoma，and discuss the clinical significance in the diagnosis and prognosis evaluation of endometrial carcinoma.Methods：Real-time quantitative reverse transcription polymerase chain reaction（RT-PCR） method was used to detect the expression level of miR-101 in 61 cases of endometrial cancer tissues.56 cases of normal endometrium tissues were used as control group，to explore the expression and clinical pathological data of endometrial carcinoma.Results：Compared with the normal endometrial tissue，expression of miR-101 in endometrial carcinoma was down-regulated，with a statistically significant difference(P<0.05).miR-101 expression levels of different clinical stages，pathological grades and depth of myometrial invasion in endometrial carcinoma were compared，differences were statistically significant(P<0.05).And the expression of miR-101 was compared in different ages，lymphatic metastasis，vascular invasion and distant metastasis of endometrial carcinoma tissues respectively，with no statistical significance(P>0.05).Conclusion：Compared with the normal endometrial tissue，miR-101 expression level in 61 cases of endometrial carcinoma tissue were significantly different，with statistical significance.miR-101 expression level was closely related to the clinical pathological parameters：Clinical stage，pathological differentiation and invasion depth.The results illustrated that the expression of miR-101 was strongly linked with the occurrence and development of endometrial carcinoma，metastasis and invasion ability.It can be for reference index of treatment and evaluating prognosis.It may be a marker of the biology of endometrial carcinoma，and may provide a potential new target for cancer targeted therapy.

References:

［1］Lucas K，Raikhel AS． Insect microRNAs： biogenesis，expression profiling and biological functions［J］．Insect Biochem Mol Biol，2013，43(1)：24-38．
［2］Zheng J，Xue H，Wang T，et al.miR-21 downregulates the tumor suppressor P12 (CDK2AP1) and stimulates cell proliferation and invasion ［J］.J Cell Biochem，2011，112(3)：872.
［3］Banno K，Yanokura M，Kisu I，et al.MicroRNA in endometrial cancer ［J］.Int J Clin Oncol，2013，18（2）：186-192.
［4］Shiozawa Y，Nie B，Pienta KJ，et al．Cancer stem cells and their role in metastasis［J］． Pharmacol Ther，2013，138(2)：285-293.
［5］Lin C，Huang F，Zhang YJ，et al． Roles of miR-101 and its target gene cox-2 in early diagnosis of cervical cancer in uygur women［J］．Asian Pac J Cancer Prev，2014，15(1)：45-48．
［6］Yu X，Jiang X，Li H，et al．miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1［J］． Stem Cells Dev，2014，23(6)：576-585．
［7］Scherr M，Elder A，Battmer K，et al． Differential expression of miR-17 approximately 92 identifies BCL2 as a therapeutic targetin BCR-ABL-positiveB-lineage acute lymphoblastic leukemia［J］．Leukemia，2013，28(3)：554-565．
［8］Yan J，Gumireddy K，Li A，et al.Regulation of mesenchymal phenotype by microRNAs in cancer［J］.Curr Cancer Drug Targets，2013，13(9)：930-934.
［9］Hiroki E，Akahira JI，Suzuki F，et al.Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas ［J］.Cancer Sci，2010，101 (1)：241.
［10］Yan GJ，Yu F，Wang B，et al.MicroRNA miR -302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1［J］.Cancer Lett，2014，345（1）：39-47.
［11］Wang HJ，Ruan HJ，He XJ，et al.MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion ［J］.Eur J Cancer，2010，46(12)：2295.
［12］Su H，Yang JR，Xu T，et al.MicroRNA-101，down-regulated in hepatocellular carcinoma，promotes apoptosis and suppresses tumorigenicity［J］.Cancer Res，2009，69(3)：1135.
［13］Strillacci A，Valerii MC，Sansone P，et al.Loss of miR-101 expression promotes Wnt/β-catenin signalling pathway activation and malignancy in colon cancer cells［J］.J Pathol，2013，229(3)：379-389.
［14］Friedman JM，Liang G，Liu CC，et al.The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 ［J］.Cancer Res，2009，69(6)：2623.
［15］Dong P，Kaneuchi M，Konno Y，et al.Emerging therapeutic biomarkers in endometrial cancer［J］.Biomed Res Int，2013，2013：130362.
［16］Banno K，Kisu I，Yanokura M，et al.Epigenetics and genetics in endometrial cancer：new carcinogenic mechanisms and relationship with clinical practice［J］.Epigenomics，2012，4（2）：147-162.
［17］Huang YW，Kuo CT，Chen JH，et al.Hypermethylation of miR-203 in endometrial carcinomas［J］.Gynecol Oncol，2014，133（2）：340-345.
［18］Tsuruta T，Kozaki K，Uesugi A，et al.MiR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer［J］.Cancer Res，2011，71（20）：6450-6462.
［19］Jiang F，Liu T，He Y，et al.MiR -125b promotes proliferation and migration of type Ⅱ endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo［J］.BMC Cancer，2011，11：425.
［20］Karaayvaz M，Zhang C，Liang S，et al.Prognostic significance of miR-205 in endometrial cancer［J］.PLoS One，2012，7（4）：e35158.
［21］Zhao ZN.MiRNA-106-b-93-25 clusters in endometrial carcinoma and the study of the mechanism of the malignant phenotype ［D］.Xi'an：The Fourth Military Medical University，2010.［赵智凝.miRNA-106b-93-25 簇在子宫内膜癌恶性表型中作用机制的研究［D］.西安：第四军医大学，2010.］
［22］Hiroki E，Akahira J，Suzuki F，et al.Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas［J］.Cancer Sci，2010，101（1）：241-249.
［23］Wei LY，Yao TT，Chen QY，et al.HeLa related genes after Gene chip to screen raised the miRNA-205 expression［J］.International J Obstetrics and Gynaecology，2012，39（5）：518-520.［韦丽娅，姚婷婷，陈庆瑜，等.基因芯片筛选上调miRNA-205 表达后HeLa 细胞相关基因［J］.国际妇产科学杂志，2012，39（5）：518-520.］
［24］Chen X，Guo X，Zhang H，et al.Role of miR-143 targeting KRAS in colorectal tumorigenesis［J］.Oncogene，2009，28(10)：1385.
［25］Dong P，Kaneuchi M，Xiong Y，et al.Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer［J］.Carcinogenesis，2014，35(4)：760-768.

Memo

Memo:
国家自然科学基金资助项目（编号：81472438，81272874）；辽宁省科技厅科研项目（编号：2013225079）；沈阳市科技局科研项目（编号：F14-158-9-47）
Last Update: 2016-12-29